Stockscreener 앱 받기
3.445
2.19%
0.075
전일 마감가:
$3.37
열려 있는:
$3.4
하루 거래량:
1.04M
Relative Volume:
0.22
시가총액:
$367.47M
수익:
-
순이익/손실:
$-258.08M
주가수익비율:
-1.2527
EPS:
-2.75
순현금흐름:
$-202.32M
1주 성능:
+20.42%
1개월 성능:
+30.95%
6개월 성능:
-68.92%
1년 성능:
-86.15%
1일 변동 폭
$3.40
$3.54
1주일 범위
$3.03
$3.54
52주 변동 폭
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
RCKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.4412 | 302.74M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.28 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.93 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.09 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.08 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Signaturefd LLC Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastMarket-leading capital gains - Autocar Professional
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - StreetInsider
Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. (RCKT) Shareholders of Class Action Lawsuit and August 11, 2025 Deadline - Barchart.com
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop - TradingView
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class ActionHagens Berman - TradingView
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
What drives Rocket Pharmaceuticals Inc. Equity Warrant stock priceTremendous growth potential - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join - GlobeNewswire
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER - GlobeNewswire
What analysts say about Rocket Pharmaceuticals Inc. Equity Warrant stockExceptional growth trajectory - Autocar Professional
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Rocket Pharmaceuticals Inc (RCKT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)August 11, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Is Rocket Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 - ACCESS Newswire
2025-07-20 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
What analysts say about Rocket Pharmaceuticals Inc. stockRapid-fire capital growth - jammulinksnews.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
2025-07-20 | RCKT LAWSUIT ALERT: Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. InvestorsLead Plaintiff Deadline August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
2025-07-19 | RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Rocket Pharmaceuticals, Inc.August 11, 2025 Deadline | NDAQ:RCKT | Press Release - Stockhouse
What drives Rocket Pharmaceuticals Inc. stock priceHigh-profit trading signals - Jammu Links News
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - StreetInsider
Rocket Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Is Rocket Pharmaceuticals Inc. Equity Warrant a good long term investmentUnrivaled growth potential - jammulinksnews.com
2025-07-18 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Before August 11, 2025Contact Levi & Korsinsky | NDAQ:RCKT | Press Release - Stockhouse
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - TradingView
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for InvestorsContact Levi & Korsinsky - cnhinews.com
(RCKT) Proactive Strategies - news.stocktradersdaily.com
2025-07-17 | RCKT LAWSUIT ALERT: Faruqi & Faruqi Notifies Rocket Pharmaceuticals Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:RCKT | Press Release - Stockhouse
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FDA Clinical Hold on RP-A501 Trial Triggers Rocket - GlobeNewswire
Rocket Pharmaceuticals (RCKT) Surges on FDA RMAT Designation for Gene Therapy - GuruFocus
Rocket Pharma stock gains on FDA RMAT status (RCKT:NASDAQ) - Seeking Alpha
Rocket Pharmaceuticals stock surges after FDA grants key designation - Investing.com Australia
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationRCKT - Barchart.com
Rocket Pharmaceuticals Receives FDA RMAT Designation - TipRanks
FDA grants RMAT designation to Rocket Pharma’s PKP2-ACM gene therapy - Investing.com Australia
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanc - GuruFocus
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.81%
0.61%
자본화:
|
볼륨(24시간):